A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients on Monotherapy Inadequately Controlled With Oral Anti-Diabetic Drug.
Phase of Trial: Phase III
Latest Information Update: 15 Jun 2016
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SYMPHONY
- Sponsors Sanofi
- 21 Jul 2009 Actual patient number (458) added as reported by ClinicalTrials.gov.
- 07 Jul 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.